ADvTECH H1 2026 slides: operating profit tops R1bn milestone

ADvTECH’s 1H26 results showed operating profit crossing R1bn for the first time, rising 14% to R1,114.8m on 8% revenue growth to R5,059.6m, with operating margin up 100bps to 22.0%. Interim EPS increased 16% to 130.8 cents and the interim dividend rose 18% to 53.0 cents, alongside completion of a R250m share buyback (repurchasing 1% at R43.55). While resourcing revenue fell 15% to R656m due to the USAID disruption, management expects improvement in 2H26; ADvTECH plans >R2bn of capex over the next three years to support university status ambitions.

Analysis

ADvTECH is increasingly a capital-allocation story, not just an earnings story. The earnings mix is moving toward tertiary education, which usually deserves a premium multiple because it carries better pricing power, lower churn, and more visible lifetime value than the school business; that should keep the market willing to pay up versus more single-product education peers. The competitive implication is that smaller listed education operators with weaker scale and less diversified delivery formats are likely to face a tougher funding backdrop if investors start anchoring on ADvTECH’s ROIC profile.

The key risk is that headline EPS growth may outrun free-cash-flow reality over the next 12-24 months. A multi-year buildout can absorb most of the company’s incremental cash generation, so the stock can look cheap on earnings while still being expensive on a cash yield basis if utilization lags or construction timelines slip. The main falsifiers are a drop in tertiary enrollment growth into the mid-single digits, margin stagnation as new campuses ramp, or any regulatory delay that pushes university-status monetization beyond the next 6-12 months.

Consensus is treating this as a defensive compounder; what may be missed is that the re-rating depends on execution of a fairly capital-intensive expansion plan. If management converts capacity into enrollments on schedule, the stock has another leg up; if not, the market may stop paying for growth and start valuing it like a slow-return infrastructure roll-up. Near term, this is more likely a ‘buy-the-dip’ name than a chase-at-any-price name.

Key Decisions for Investors

• Long JSE:ADH / URANF on a 3-5% pullback over the next 1-3 months; risk/reward is attractive if tertiary enrollment remains >10% and margins hold above 21.5%.
• Pair trade over 6-12 months: long JSE:ADH vs short JSE:COH as a relative-quality trade; ADH has better mix, stronger operating leverage, and more credible capital returns.
• Set a catalyst alert for the next regulatory update on private university status; if approval slips beyond 2H26, reduce exposure because the re-rating thesis weakens materially.
• Watch FCF conversion rather than EPS in the next two reporting cycles; if excess cash falls below management’s R400m-R500m guide, the buyback/dividend support for the multiple becomes less durable.